HIV mutation literature information.


  HIV type 1 drug resistance patterns among patients failing first and second line antiretroviral therapy in Nairobi, Kenya.
 PMID: 25487529       2014       BMC research notes
Abstract: In addition, among patients failing second-line (20), six patients (30%) had NNRTI resistance; two patients on K103N and G190A mutations while V106A, Y184V, A98G, Y181C mutations per patient were also detected.
Result: Single occurring mutations of V106A occurred as expected in a patient who had NVP regimen.
Result: These mutations were M184V (n = 1), T215Y (n = 2), V106A (n = 1), A98G (n = 1), Y18C1C (n = 1), G190A (n = 1) and V108IV (n = 1).


  The development of drug resistance mutations K103N Y181C and G190A in long term Nevirapine-containing antiviral therapy.
 PMID: 25926857       2014       AIDS research and therapy
Discussion: The rank of fitness among mutant viruses was as follows: wild type (WT) >= Y181C >= K103N >= G190A >= V106A >= P236L >= G190S.


  Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.
 PMID: 22842995       2013       AIDS (London, England)
Abstract: Conversely, Y181C, Y181I, V106A, H221Y and F227L were more prevalent following NVP than EFV failures.


  Short communication: HIV type 1 transmitted drug resistance and evidence of transmission clusters among recently infected antiretroviral-naive individuals from Ugandan fishing communities of Lake Victoria.
 PMID: 23173702       2013       AIDS research and human retroviruses
Abstract: Nonnucleoside reverse transcriptase inhibitor (NNRTI) drug resistance mutation K103N was identified in two individuals and V106A in one (6%) suggesting that the level of TDR was moderate in this population.


  Human APOBEC3G-mediated hypermutation is associated with antiretroviral therapy failure in HIV-1 subtype C-infected individuals.
 PMID: 23443042       2013       Journal of the International AIDS Society
Table: V106A


  Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy.
 PMID: 23469241       2013       PloS one
Table: V106A/M


  Restriction fragment mass polymorphism (RFMP) analysis based on MALDI-TOF mass spectrometry for detecting antiretroviral resistance in HIV-1 infected patients.
 PMID: 23480551       2013       Clinical microbiology and infection
Abstract: The concordance rates between the RFMP and direct sequencing assays for the examined codons were 97% (K65R), 97% (T69Ins/D), 97% (L74VI), 97% (K103N), 96% (V106AM), 97% (Q151M), 97% (Y181C), 97% (M184VI) and 94% (T215YF) in the reverse transcriptase coding region, and 100% (D30N), 100% (M46I), 100% (G48V), 100% (I50V), 100% (I54LS), 99% (V82A), 99% (I84V) and 100% (L90M) in th


  Identification and characterization of a novel HIV-1 nucleotide-competing reverse transcriptase inhibitor series.
 PMID: 23545531       2013       Antimicrobial agents and chemotherapy
Abstract: The antiviral potency of compound A was unaffected by the presence of nonnucleotide RT inhibitor (NNRTI) mutations tested (L100I, K103N/Y181C, V106A, or Y188L).


  Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens.
 PMID: 23840622       2013       PloS one
Result: Additional NNRTI-resistance mutations not shown in Table 4 included (i) A98G, which occurred in 3.3% of NNRTI-treated patients; (ii) V106A, which occurred in 0.6% of NNRTI-treated patients; (iii) E138G/Q, which occurred in 0.9% and 0.9% of patients, respectively; (iv) V179D/E/T/F, which occurred in 8.5%, 0.7%, 0.5%, and 0% of NNRTI-treated patients respectively; (v) Y181I/V, which occurred in one and no patient, respectively; (vi) H221Y, which occurred in 5.9% of EFV-treated and 9.3% of NVP-treated patients (p<0.001); (vii) P225H, which occurred in 13.6% of EFV-treate


  Persistence of HIV-1 transmitted drug resistance mutations.
 PMID: 23904291       2013       The Journal of infectious diseases
Table: V106A



Browser Board

 Co-occurred Entities




   Filtrator